updates (additional information)
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivimed Labs has disclosed additional details regarding a CBI (Banking Securities Fraud Branch, Bengaluru) case. CBI registered case no. RC 03(E)/2025/CBI/BSFB/BLR on November 19, 2025 against the company and its four directors under charges of conspiracy, cheating, forgery, and Prevention of Corruption Act. State Bank of India has classified Vivimed Labs' account as 'fraud' and CBI conducted search & seizure on January 20, 2026. The CFO and CS received a notice in this regard. The company then approached the High Court of Telangana at Hyderabad, which granted an interim stay on February 6, 2026, restraining all further proceedings and any coercive action against the company and its directors. The company states the financial impact cannot be quantified at this stage.
The High Court interim stay provides temporary relief from coercive action, which is mildly positive for the company in the short term. However, the underlying CBI case, criminal charges against directors, and SBI's fraud classification remain serious overhangs that could weigh on the stock and raise concerns for shareholders about governance and long-term financial impact.